Fundamenta Therapeutics, Ltd.
12
0
1
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 12 trials
0%
0 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Efficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Role: collaborator
Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma
Role: collaborator
ThisCART19A for B-NHL Relapsed After Auto-CAR T
Role: collaborator
ThisCART19A Bridging to alloHSCT for R/R B-ALL
Role: collaborator
Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B Cell Malignancies After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy
Role: collaborator
Safety and Efficacy of ThisCART19A Bridging Hematopoietic Stem Cell Transplantation in Patients With Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia
Role: lead
Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma
Role: collaborator
Safety and Efficacy of ThisCART19 in Patients With Refractory or Relapsed B Cell Malignancies
Role: lead
Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies
Role: lead
Safety and Clinical Activity of ThisCART22 in Patients With r/r Non-Hodgkin's B Cell Lymphoma
Role: lead
Safety and Clinical Activity of ThisCART19 in Patients With r/r Non-Hodgkin's B Cell Lymphoma
Role: lead
Safety and Efficacy of ThisCART22 in Patients With Refractory or Relapsed B Cell Malignancies
Role: lead
All 12 trials loaded